Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1?

Menopause

Volumn 18, Issue 8, 2011, Pages 833-834

  Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILENIN; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; EDITORIAL; FEMALE; FOLLICULAR PHASE; HUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PREMATURE OVARIAN FAILURE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CONTRACEPTIVE AGENTS, FEMALE; ESTRADIOL; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEINS; RECEPTORS, PROGESTERONE;

EID: 80051543866     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182260321     Document Type: Editorial

References (15)

1. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:726.
2. Bhavnani BR, Tam S-P, Lu XF. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ER>and ER
3. Stanczyk FZ, Chaikittisilpa S, Roy S. Pharmacologic deficiency in Women's Health Initiative study. J Reprod Med 2003;48:485-486. (Pubitemid 36741584)
4. Gerdes D, Wehling M, Leube B, Falkenstein E. Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 1998;379:907-911. (Pubitemid 28369381)
5. Losel RM, Besong D, Peluso JJ, Wehling M. Progesterone receptor membrane component 1Vmany tasks for a versatile protein. Steroids 2008;73:929-934.
6. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granuloss cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008;149:534-543. (Pubitemid 351159360)
7. Rohe HJ, Ahmed IS, Twist KE, Craven RJ. PGRMC1 ( progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 2009;121:14-19.
8. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16-36. (Pubitemid 47211947)
9. Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008;10:R85.
10. Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230-239.
11. Schuster J, Karlsson T, Karlström P-O, Poromaa IS, Dahl N. Downregulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS). Reprod Biol Endocrinol 2010;8:58-63.
12. Crudden G, Chitti RE, Craven RJ. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006;316:448-455. (Pubitemid 41832625)
13. Neubauer H, Yang Y, Seeger H, et al. The presence of a membranebound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011;18: 845-850.
14. Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. J Horm Molec Biol Clin Invest. In press.
15. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. (Pubitemid 350179584)